May 26, 2010 - Wearable Defibrillator Showcased at Heart Failure Congress


A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637


LifeVest Provides Patients With Heart Failure Protection from Sudden Cardiac Arrest

May 26, 2010CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, today announced that it will display the LifeVest® Wearable Defibrillator in Booth D1 at the European Society of Cardiology Heart Failure Congress 2010, being held from 29 May  through 1 June  in Berlin, Germany. 

The LifeVest Wearable Defibrillator is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing medical condition, and until their permanent risk of SCA is established.

The risk of sudden cardiac death following a myocardial infarction is the highest in the first 30 days and patients with heart failure are at 4-6 times greater risk. The LifeVest protects these patients during this time of highest risk while they are being optimized on medical therapy. A patient’s condition can improve from the benefits of medical therapy, including meaningful improvement in ejection fraction.  However, medical therapy and stabilization can take up to three months or more. 

“Approximately 3.6 million people in Europe are newly diagnosed with heart failure every year,” said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL. “The LifeVest is an important therapy in the continuum of care for patients with heart failure, allowing a physician to manage a patient’s changing condition while protecting him or her from sudden cardiac arrest.”

ZOLL recently established a direct sales force in Germany dedicated to the LifeVest® business in that country, since Germany represents the most significant market opportunity in Europe for the LifeVest, based on both size and overall healthcare policy. In addition to the German initiative, the LifeVest is also marketed in Europe via distribution partners located in the United Kingdom, Italy, France, and The Netherlands.  

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA.  The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is used for a wide range of patient conditions, including following a heart attack, before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure that places patients at particular risk.

To date, the LifeVest has been prescribed for over 25,000 patients. 

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit

Copyright © 2010 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL and LifeVest are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.